Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ORMP - US68403P2039 - Common Stock

3.47 USD
-0.01 (-0.29%)
Last: 1/28/2026, 4:05:13 PM

ORMP Key Statistics, Chart & Performance

Key Statistics
Market Cap138.11M
Revenue(TTM)2.00M
Net Income(TTM)43.85M
Shares39.80M
Float33.71M
52 Week High3.71
52 Week Low1.82
Yearly DividendN/A
Dividend Yield7.37%
EPS(TTM)1.24
PE2.8
Fwd PEN/A
Earnings (Next)03-25
IPO2002-04-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
ORMP short term performance overview.The bars show the price performance of ORMP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ORMP long term performance overview.The bars show the price performance of ORMP in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of ORMP is 3.47 USD. In the past month the price increased by 17.97%. In the past year, price increased by 55.36%.

ORAMED PHARMACEUTICALS INC / ORMP Daily stock chart

ORMP Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP is one of the better performing stocks in the market, outperforming 92.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ORMP Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ORMP. While ORMP has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ORMP Financial Highlights

Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of 1.24. The EPS increased by 726.67% compared to the year before.


Industry RankSector Rank
PM (TTM) 2192.6%
ROA 19.89%
ROE 21.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%333.33%
Sales Q2Q%N/A
EPS 1Y (TTM)726.67%
Revenue 1Y (TTM)-100%

ORMP Forecast & Estimates

6 analysts have analysed ORMP and the average price target is 3.32 USD. This implies a price decrease of -4.47% is expected in the next year compared to the current price of 3.47.


Analysts
Analysts43.33
Price Target3.32 (-4.32%)
EPS Next Y825.33%
Revenue Next YearN/A

ORMP Ownership

Ownership
Inst Owners18.24%
Ins Owners12.73%
Short Float %1.26%
Short Ratio1.7

About ORMP

Company Profile

ORMP logo image Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Company Info

ORAMED PHARMACEUTICALS INC

1185 Avenue Of The Americas, 3Rd Floor

New York City NEW YORK 10036 US

CEO: Nadav Kidron

Employees: 13

ORMP Company Website

ORMP Investor Relations

Phone: 16468441164

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What does ORMP do?

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.


What is the current price of ORMP stock?

The current stock price of ORMP is 3.47 USD. The price decreased by -0.29% in the last trading session.


Does ORAMED PHARMACEUTICALS INC pay dividends?

ORAMED PHARMACEUTICALS INC (ORMP) has a dividend yield of 7.37%. The yearly dividend amount is currently 0.


What is the ChartMill technical and fundamental rating of ORMP stock?

ORMP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Can you provide the sector and industry classification for ORAMED PHARMACEUTICALS INC?

ORAMED PHARMACEUTICALS INC (ORMP) operates in the Health Care sector and the Pharmaceuticals industry.


What is the Price/Earnings (PE) ratio of ORAMED PHARMACEUTICALS INC (ORMP)?

The PE ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.8. This is based on the reported non-GAAP earnings per share of 1.24 and the current share price of 3.47 USD.


Can you provide the short interest for ORMP stock?

The outstanding short interest for ORAMED PHARMACEUTICALS INC (ORMP) is 1.26% of its float.